ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (OTCQX:ANPCY) announced it will present on the Investor Meet Company platform at 11:00 am (BST) on April 28, 2023. The session will feature insights from CEO Andrew Newland and CFO Ian Griffiths, focusing on the company's strategic activities. Investors have the opportunity to submit questions until April 26, 2023, that will be addressed during the presentation. ANGLE is known for its Parsortix system, the first FDA-cleared device for harvesting intact circulating tumor cells (CTCs) from blood, primarily for metastatic breast cancer. The technology shows promising clinical results in ongoing studies, demonstrating high accuracy in cancer detection and analysis. For details and registration, investors can visit the provided link.

ANGLE plc (OTCQX:ANPCY) reported significant milestones in its 2022 financial results, marking a breakthrough year with FDA clearance for the Parsortix PC1 Clinical System. This system allows for the harvesting of intact cancer cells from blood samples, a first in its class. The company achieved revenue of £1.0 million in 2022, consistent with 2021, while losses rose to £21.7 million due to planned investments. An encouraging performance in Q1 2023 reported strong year-on-year revenue growth. A major partnership with Solaris Health focuses on prostate cancer, and additional contracts with pharma clients highlight increasing demand for its services. ANGLE's healthy cash position stands at £31.9 million, complemented by ongoing R&D Tax Credits, setting a solid foundation for growth.

ANGLE plc has announced a development partnership with BioView Ltd. to create a circulating tumor cell (CTC) HER2 assay for breast cancer. This collaboration utilizes ANGLE's FDA-cleared Parsortix PC1 Clinical System and BioView's microscopy technology. The first phase is projected to generate approximately £1.2 million in revenue. As breast cancer treatment evolves, there is a significant opportunity to develop a quantitative HER2 assay that can monitor patients' HER2 status over time. The HER2-low breast cancer segment, accounting for 55% of breast cancer cases, is gaining attention, especially with the introduction of targeted therapies like ENHERTU. Analysts anticipate a potential US$3 billion annual increase in sales value due to this market expansion.

ANGLE plc has presented a poster at the AACR annual meeting 2023 showcasing the capabilities of its Parsortix system to analyze circulating tumor cells (CTCs) in metastatic breast cancer (MBC) patients. The research demonstrates the successful combination of immunofluorescent (IF) staining and HER2 FISH analysis, achieving over 90% analytical sensitivity and specificity. In a study of 16 MBC patients, CTCs were identified in 81%, with 38.5% of those exhibiting high HER2 expression. The findings highlight the commercial potential for a CTC-based HER2 assay, which allows for ongoing monitoring of HER2 status, addressing an unmet medical need and potentially expanding the HER2 diagnostic market. ANGLE's innovation aligns with evolving treatment strategies for patients with varying HER2 levels.

ANGLE plc has announced a contract with Crescendo Biologics to utilize its Portrait Flex Assay in Crescendo's ongoing Phase 1 clinical trial for CB307, a drug targeting prostate cancer. The assay, developed for detecting circulating tumor cells (CTCs), boasts over 90% sensitivity and specificity, crucial for identifying druggable targets in cancer treatment. Crescendo will process patient samples using ANGLE's Parsortix system at its accredited laboratories. Both companies express enthusiasm about the collaboration, indicating potential for future partnerships. This contract highlights the growing importance of CTC biomarkers in clinical trials, giving ANGLE a stronger foothold in the immuno-oncology sector.

ANGLE plc (OTCQX:ANPCY) will release its preliminary results for the year ended 31 December 2022 on April 21, 2023. A virtual meeting for analysts is scheduled at 10:00 am BST on the same day, with registration required in advance. The company's liquid biopsy technology, notably the Parsortix system, is FDA cleared for use in metastatic breast cancer, serving as the first approved medical device to harvest intact circulating cancer cells from blood. ANGLE aims to enhance cancer diagnostics, supported by extensive clinical studies and collaborations with leading cancer centers.

ANGLE plc (OTCQX:ANPCY), a leader in liquid biopsy, announced on March 10, 2023, the approval of share options under its Remuneration Policy. The Remuneration Committee granted up to 6,000,000 LTIP options to executive directors and up to 9,000,000 Staff Share Options to employees. Following this issuance, total options outstanding will amount to 41,133,147 shares, equating to approximately 13.6% of the issued share capital. The exercise price for Staff Share Options is £0.2575. The LTIP options will vest based on performance conditions related to share price growth over three years, designed to enhance shareholder value.

ANGLE plc reported a significant change in voting rights as Global Frontier Partners, LP acquired an additional stake in the company. The acquisition increased their voting rights from 3.65% to 5.32%, totaling 13,868,946 shares. This threshold was reached on March 7, 2023, with the notification sent on March 8, 2023. Global Frontier Investments, LLC serves as the general partner for the acquired shares, impacting the control dynamics within the company. The increase in holdings signifies a noteworthy investment in ANGLE plc, which could influence future strategic decisions and shareholder value.